A Multi-center, Phase Ib Study of MEK (Mitogen Activated Protein Kinase/ERK Kinase) Inhibitor BAY86-9766 Plus Gemcitabine in Asian Patients With Advanced or Refractory Solid Tumors
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label
Plasma concentration of BAY86-9766
Multiple time points up to 6 day
No
Bayer Study Director
Study Director
Bayer
Japan: Pharmaceuticals and Medical Devices Agency
14747
NCT01764828
February 2013
June 2014
Name | Location |
---|